GLAXO vs NATCOPHARM: Stock Comparison
GLAXOSMITHKLINE PHARMA LT is the larger company by market capitalisation. GLAXOSMITHKLINE PHARMA LT shows a higher ROE, a higher dividend yield and faster revenue growth, while NATCO PHARMA shows a lower P/E and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
GLAXO leads 7; NATCOPHARM leads 4 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | GLAXO | NATCOPHARM |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | GLAXO | NATCOPHARM |
|---|---|---|
| Live Price | ₹2,505.9 | ₹787.55 |
| Day Change | -0.37% | 0% |
| Volume | 819 | 64,395 |
| 52-Week High | ₹3,120.7 | ₹1,226.8 |
| 52-Week Low | ₹2,088.1 | ₹773.6 |
| Distance from 52W High | -19.7% | -35.8% |
Valuation
| Metric | GLAXO | NATCOPHARM |
|---|---|---|
| Market Cap | ₹42,795 Cr | ₹15,532 Cr |
| P/E Ratio | 39.89x | 13.49x |
| P/B Ratio | 18.79x | 1.67x |
| EPS | ₹63.05 | ₹10.53 |
| Book Value | ₹133.85 | ₹470.06 |
| Dividend Yield | 2.28% | 0.57% |
Growth
| Metric | GLAXO | NATCOPHARM |
|---|---|---|
| Revenue Growth (TTM YoY) | 2.1% | -39.6% |
| EPS Growth (TTM YoY) | 5.7% | -34.1% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | GLAXO | NATCOPHARM |
|---|---|---|
| ROE | 45.34% | 14.98% |
| ROCE | 87.77% | 15.1% |
| Net Margin | 27.29% | 34.78% |
| Operating Margin | 36.86% | 38.85% |
| Debt to Equity | 0x | 0.08x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | GLAXO | NATCOPHARM |
|---|---|---|
| Promoter Holding | 75% | 49.12%▼ 0.02 pp |
| FII Holding | 4.75%▼ 0.04 pp | 16%▼ 0.99 pp |
| DII Holding | 8.48%▲ 0.68 pp | 6.16%▲ 0.54 pp |
| Public Holding | 11.77%▼ 0.64 pp | 28.45%▲ 0.48 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: GLAXOSMITHKLINE PHARMA LT and NATCO PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.